3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
23
Neoplasm Metastasis
5
Carcinoma, Renal Cell
5
Recurrence
3
Neoplasms
3
Multiple Myeloma
3
Colorectal Neoplasms
3
Carcinoma, Hepatocellular
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Leukemia
2
Kidney Neoplasms
2
Hematologic Neoplasms
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Sarcoma
1
Peritoneal Neoplasms
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Neoplasms, Plasma Cell
1
Mycosis Fungoides
1
Lymphoma, T-Cell
1
Lymphoma, Follicular
1
Lymphoma
1
Liver Neoplasms
1
Liver Cirrhosis
1
Leukemia-Lymphoma, Adult T-Cell
1
Hepatitis C, Chronic
1
Interventions
Cisplatin
7
Etoposide
6
Amifostine
6
Radiotherapy
5
Drug Therapy
5
Cyclophosphamide
5
apatinib
4
Methotrexate
4
Filgrastim
4
Cytarabine
4
sodium thiosulfate
3
Methylprednisolone
3
Carboplatin
3
pegfilgrastim
2
glucarpidase
2
etoposide phosphate
2
Voriconazole
2
Vincristine
2
Social Determinants of Health
2
Pyridoxine
2
Nivolumab
2
Gemcitabine
2
Doxorubicin
2
Docetaxel
2
Chemotherapy, Adjuvant
2
Capecitabine
2
trastuzumab deruxtecan
1
selinexor
1
sargramostim
1
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Drug-Related Side Effects and Adverse Reactions
×
Introns
×
Clear all
NCT00221702
2010-10-13
EADO
University Hospital, Bordeaux
Phase 3
Completed
898 enrolled